CI

At a glance

ClinicalIndex Comparison Record
Phase 4Active· 15,448 enrolled
Drug / intervention
Egg based influenza vaccines +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03734237
NCT03734237Phase 4Active
CompareCT.gov

A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD

Henry M. Jackson Foundation for the Advancement of Military Medicine·interventional·Posted Nov 7, 2018·Updated Apr 2, 2026

In Brief

A Phase 4 clinical trial evaluating Egg based influenza vaccines, Recombinant influenza vaccines, and 1 other intervention for Influenza and 2 related conditions. Active but no longer recruiting, targeting 15,448 participants across 9 sites.

Detailed Summary

A total of 18,000 eligible subjects (or 6,000 subject distributed evenly between the 3 study arms) will be enrolled. Eligible subjects will be randomized in 1:1:1 (cell-culture-based vaccine, the recombinant vaccine, or the egg-based vaccine) over four influenza seasons (2018-2019, 2019-2020, 2020-2021, and 2021-2022).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza, Influenza-like Illness, Influenza Vaccines
CountriesUnited States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID), Food and Drug Administration (FDA), US Department of Defense Armed Forces Health Surveillance Center, Naval Health Research Center, United States Air Force School of Aerospace Medicine, Uniformed Services University of the Health Sciences, Defense Health Agency

Timeline

Phase 4ActiveOverdue
20192020202120222023202420252026
First PostedNov 7, 2018
Enrollment StartNov 6, 2018
Primary CompletionJul 7, 2022
Study CompletionJun 30, 2026
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 7.7 years ago

Interventions

Egg based influenza vaccinesbiological

Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.

Recombinant influenza vaccinesbiological

Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.

Cell-culture based influenza vaccinesbiological

Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.